COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Antioxidant Supplementation in Patients With Kashin-Beck Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376025
Recruitment Status : Unknown
Verified February 2008 by Innovative Humanitarian Solutions.
Recruitment status was:  Recruiting
First Posted : September 14, 2006
Last Update Posted : February 22, 2008
University of Houston - Victoria
Information provided by:
Innovative Humanitarian Solutions

Brief Summary:
The purpose of this study is to determine whether antioxidant supplementation can have a positive health effect on patients suffering from Kashin-Beck disease.

Condition or disease Intervention/treatment Phase
Kashin-Beck Disease Dietary Supplement: Biological Antioxidant Supplementation Phase 2

Detailed Description:

Current research regarding Kashin-Beck disease, (KBD) have identified dramatic deficiencies of both selenium and iodine in patients with this disease. Initial supplementation of these trace minerals provided no measurable benefit to the affected population. Research conducted by Innovative Humanitarian Solutions, suggests that such deficiencies may not be causal, but markers of an underlying condition of extreme oxidative stress brought on by the improper functioning of the Glutathione Peroxidase enzyme in synthesizing H202 during periods of critical cellular development, primarily in mesenchymal cell development.

The purpose of this trial is to determine the efficacy of antioxidant supplementation in aiding the Glutathione Peroxidase enzyme in its proper function and thereby reducing oxidative stress and enabling the uptake of selenium and iodine which are necessary for proper bone growth and development.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of the Effects of Antioxidant Supplementation in Patients Suffering From Kashin-Beck Disease
Study Start Date : July 2007
Estimated Primary Completion Date : January 2009
Estimated Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antioxidants

Intervention Details:
  • Dietary Supplement: Biological Antioxidant Supplementation
    Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.

Primary Outcome Measures :
  1. Score on FLACC or Word Graphic pain rating scale at 3, 6, 9 months [ Time Frame: One Year ]

Secondary Outcome Measures :
  1. Increase in serum selenium concentrations at 6 months [ Time Frame: Six Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   9 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically diagnosed patients with Kashin-Beck disease

Exclusion Criteria:

  • less than 24 hours from admission to ICU
  • Patients who are moribund
  • Lack of commitment to program
  • Absolute contraindication to enteral nutrients
  • Severe acquired brain injury
  • Pregnant or lactating patients
  • Previous randomization in this study
  • Enrollment in a related interventional study
  • Child's class C liver disease Metastatic cancer with life expectancy < 6 months Seizure disorder requiring anticonvulsant medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376025

Layout table for location contacts
Contact: Jeff C Cokenour, B.S. 832-863-5690
Contact: Don Heath, B.S.

Layout table for location information
China, Tibet
Lhasa Prefecture and surrounding villages Recruiting
Lhasa, Tibet, China, 850000
Sub-Investigator: Don Heath         
Sponsors and Collaborators
Innovative Humanitarian Solutions
University of Houston - Victoria
Layout table for investigator information
Study Chair: Richard Gunasekera, Ph.D. University of Houston - Victoria
Principal Investigator: Jeff C Cokenour, B.S. Innovative Humanitarian Solutions
Principal Investigator: Minh Han, M.D. Innovative Humanitarian Solutions
Additional Information:
Molecular Biology of selenium with its implications for metabolism. Raymond F. Burke, Division of Gastroenterology, division of Medicine and center in molecular toxicology, Vanderbilt University school of medicine, Nashville, Tenn 37232, USA

Layout table for additonal information
Responsible Party: Richard S. Gunasekera, Ph.D., Study Chair and P.I., University of Houston - Victoria Identifier: NCT00376025    
Other Study ID Numbers: KB001
First Posted: September 14, 2006    Key Record Dates
Last Update Posted: February 22, 2008
Last Verified: February 2008
Keywords provided by Innovative Humanitarian Solutions:
Kashin-Beck Disease
Kashin-Beck Osteoarthropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Kashin-Beck Disease
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs